Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax

Total 125 results found. Search for [ Abbreviated New Drug Applications ]

Results 100 to 120 of 125
New Delhi, September 16, 2014
According to IT company IMS health, the estimated sales in 2014 for Glipizide ER tablets is US $90.1 million, the company said in a BSE filing.

Rahul Oberoi/Money Today
April 29, 2014
Experts says Ranbaxy deal is excellent for Sun Pharma. It will be a big boost to the investment morale in the domestic market. It will help Sun Pharma establish full spectrum presence, both therapeutically and geographically.

E. Kumar Sharma
February 17, 2014
Margaret A Hamburg, US Food and Drug Administration (USFDA) Commissioner on her first official visit to India, has been visiting the Taj Mahal and also writing down her impressions of the meetings she has had in India. 

BT Online Bureau
New Delhi, December 10, 2013
Strides Arcolab on Tuesday announced a special dividend Rs 500 per equity share of Rs 10 each to the shareholders of the company.

New Delhi, December 5, 2013
The company, however, said it has agreed to a hold back of $250 million due to a warning letter received by it from the USFDA for one of its injectable facilities in Bangalore.

BT Online Bureau
New Delhi, December 5, 2013
Stock of Strides Arcolab fell more than 12 per cent on Thursday after the firm informed BSE that it has completed the sale of its Agila Specialties division to Nasdaq-listed  Mylan Inc for a total consideration of up to $1.75 billion.

E Kumar Sharma
September 17, 2013
Ranbaxy has been pinning its hopes on Mohali after the FDA slapped import bans on its Paonta Sahib and Dewas plants in 2008. But the extension of the Consent Decree to the Punjab plant means the drug maker is barred from supplying any products from it.

Washington, August 12, 2013
Many Indian drugmakers will soon have to bear higher costs for sale of products in American markets, as the US health regulator FDA is hiking the fees for generic drugmakers by up to 48 per cent from October.

New Delhi, July 13, 2013
Glenmark Pharmaceuticals said its applications for generic version of epilepsy treatment drug Vimpat in America have been challenged by UCB Inc and other companies in a US court.

New Delhi, June 19, 2013
Drug firm Glenmark Pharmaceuticals said it has received US health regulator's approval to market Riluzole tablets, used in treating nervous system disorder, in the American market.

Pritam P Hans
May 23, 2013
Demand in India for Bitcoins, a virtual currency maintained by peer networks, is largely from speculators - as it is worldwide.

Pritam P. Hans
April 25, 2013
Demand in India for Bitcoins, a virtual currency maintained by peer networks, is largely from speculators - as it is worldwide.
March 25, 2013
Generic drugmaker Mylan Inc. will acquire Agila Specialties - a developer, manufacturer and marketer of high-quality generic injectible products - from Strides Arcolab for $1.6 billion (Rs 8,674.2 crore) in cash.

Rahul Oberoi
January 15, 2013
There is widespread optimism that the pro-industry decisions by the government of the last few months and a lowering of interest rates - which is widely expected - accompanied by an economic recovery, however small, will work their magic on equity markets in the next few quarters.

Rahul Oberoi/Money Today
January 15, 2013
Market analysts are positive on retail, media and aviation sectors in which the government allowed more foreign direct investment in September 2012.

New Delhi, December 27, 2012
Aurobindo Pharma says it has received final approval by the US health regulator to manufacture and market Nafcillin for injection used for treating bacterial infections in the American market.

New Delhi, September 20, 2012
Glenmark Pharmaceuticals said it has received tentative approval from the US health regulator for its generic Rizatriptan Benzoate tablets used for treating migraine attacks.

Shalini S. Dagar
July 6, 2010
Two years after it slammed into a US regulatory wall, Ranbaxy Laboratories, under its Japanese owners, is working the hard way to be back among the stars.

Suman Layak
May 26, 2010
For most of its 40 years, Lupin seemed to be just another Indian pharma company trying to make hay in the US generics market. Today, it is a global generics firm to reckon with, taking on giant Teva on the value-creation front.

E. Kumar Sharma
November 15, 2009
While MNCs are invading India in a desperate quest for new markets, Indian pharma firms are struggling to expand and rise up the value chain in a tough, competitive environment.

PAGES 6 OF 7  67